Overview

The Use of Sugammadex in the Critically Ill

Status:
Unknown status

Trial end date:
2021-07-01

Target enrollment:
0

Participant gender:
All

Summary

Moderate and Deep neuromuscular blockade (rocuronium administered to a train of four count 0 and post-tetanic count of 1-2) in critically ill patients needing intubation or procedures can be reversed immediately and effectively by sugammadex avoiding unnecessary paralysis in an already weakened population

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

McGill University Health Center
McGill University Health Centre/Research Institute of the McGill University Health Centre

Treatments:

Glycopyrrolate
Neostigmine
Rocuronium

Criteria

Inclusion Criteria:

- Adult patients requiring intubation in the intensive care unit

Exclusion Criteria:

- Patients younger than 18 yr, to have known or suspected neuromuscular disease,
allergies to medications to be used during intubation, a (family) history of malignant
hyperthermia or severe renal insufficiency (glomerular filtration rate <30 ml/h) will
not be eligible.